Robert Liwski

Robert Liwski

Auto-generated profile, based on publicly available information

Robert Liwski

Dalhousie University

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
CNChristopher Naugler
Christopher Naugler
RLRobert Liwski
Robert Liwski
Chronic myelogenous leukemia (CML) results from a translocation (9;22), which creates an immunogenically active BCR-ABL fusion protein. Previous authors have reported both positive and negative human leukocyte antigen (HLA) associations with CML, possibly as the result of different antigenic peptide presentation capabilities. We examined HLA Class I and Class II antigen polymorphisms in 31 patients with CML and compared these with 258 control individuals drawn from Maritime Canada. HLA-B*13 (odds ratios (OR) 4.92, 95% confidence intervals (CI) 1.70-14.24), HLA-B*55 (OR 4.50, 95%CI 1.07-18.99), and HLA-DRB1*16 (OR 4.07, 95%CI 1.17-14.09) were all statistically significant risk markers for CML. After a Bonferroni correction for Type I error was applied, only HLA-B*13 remained statistically significant as a risk marker for CML. No HLA antigens were found to be protective. The lack of reproducibility of HLA antigen associations with CML suggests that these associations are population-specific and may not be due to HLA antigen-restricted differences in CML antigen presentation.

25 January 2023 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
TSTiago Schiavo
Tiago Schiavo
JMJuliana Montagner
Juliana Montagner
EKElizete Keitel
Elizete Keitel
AGAnna Greenshields
Anna Greenshields
RLRobert S Liwski
Robert S Liwski
JNJorge Neumann
Jorge Neumann
Introduction: The main strategy to reduce the immunogenicity of transplanted grafts is to seek maximum compatibility between alloantigens in the donor-recipient pair. It is understood that the virtual crossmatch (VXM) can be a good tool in the evaluation of the donor / recipient pair and that a broader application of these protocols will improve the pre-transplant immunological risk assessment. The aim of this study was to correlate the physical flow crossmatches results, looking at different mean fluorescence intensity (MFI) values of the donor specific antibodies (DSA), and the probability of a positive crossmatch. We also aimed to validate this tool using a well standardized flow crossmatch protocol. Methods: We performed a total of 15,217 FCXM between 2015 and 2019. All were tested by the Halifax Flow Cytometer Crossmatch (FCXM) protocol, with cells from deceased donors and serum from renal recipients. For this analysis we selected only samples that had one or two DSA per locus (N = 1,081), when the MFI was above 1,000, and they were divided according to the allelic group recognized by the antibody (anti-HLA-A, B, C, DR or DQ) looking at the probability of a positive crossmatch with different MFI values of the DSAs. Combinations among them were also analyzed in the same way (N=175). Results: In the presence of an exclusive DSA against the allelic groups A, B and DR, with an index MFI above 5,000, all the FCXM were positives. With exclusively antibodies against groups C or DQ, all cases with DSAs above 15,000 MFIs were positives. With two or more DSAs anti A and/or B, and/or DR, when their MFIs sums exceeded 5,000, all FCXM results against B cells were positive. The presence of anti-Class I DSAs (A, B and A+B), regardless of the MFI value, was responsible for 71% (N=424 of 601) of the T cell positivity and 77% (N=460 of 661) in the B cell crossmatches. The presence of only anti-Class II DSAs (DR and DQ) accounted for 55% (N=168 of 303) of FCXM positivity in B cells. The overall mean of the MFI of the DSAs was higher in the FCXM positive group when compared to negative crossmatch. The group with sum of DSAs A (N=217) showed that when the sum was 4,000 MFI or higher, there was a 24 times higher probability for a positive B cell crossmatch when compared with lowers MFIs. Conclusions: Our results show a strong association between the DSA MFI and the FCXM result. The data here presented confirm the results of our previous studies, justifying the VXM standard used by our center, proving to be a good tool to streamline the selection of transplant recipients and facilitate the sharing of organs from national donors.

1 October 2011 in Human Immunology
Verified
Journal Article
Closed access
RLRobert Liwski
Robert Liwski
GAGeoff Adams
Geoff Adams
GPGeoff Peladeau
Geoff Peladeau
DEDavid Eckels
David Eckels
RBRobert Bray
Robert Bray
HGHoward Gebel
Howard Gebel

25 January 2023 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
TSTiago Schiavo
Tiago Schiavo
JMJuliana Montagner
Juliana Montagner
EKElizete Keitel
Elizete Keitel
AGAnna Greenshields
Anna Greenshields
RLRobert S Liwski
Robert S Liwski
JNJorge Neumann
Jorge Neumann
Introdução: A principal estratégia para reduzir a imunogenicidade dos enxertos transplantados é buscar a máxima compatibilidade entre os aloantígenos no par doador-receptor. Entende-se que a prova cruzada virtual (VXM) pode ser uma boa ferramenta na avaliação da dupla doador/receptor e que uma aplicação mais ampla desses protocolos melhorará a avaliação do risco imunológico pré-transplante. O objetivo deste estudo foi correlacionar os resultados das provas cruzadas por citometria de fluxo (FCXM), observando os diferentes valores médios de intensidade de fluorescência (MFI) e o alvo dos anticorpos doador específicos (DSA), com a probabilidade de uma prova cruzada positiva. Usamos para isso o protocolo Halifax de prova cruzada por citometria de fluxo. Métodos: Foram realizados um total de 15.217 FCXM entre 2015 e 2019. Todos foram testados pelo protocolo Halifax Flow Cytometer Crossmatch (FCXM), com células de doadores falecidos e soro de receptores renais. Para esta análise, selecionamos apenas as amostras que apresentavam um ou dois DSAs por locus (N = 1.081) quando o MFI estava acima de 1.000. Esses foram divididos de acordo com o grupo alélico reconhecido pelo anticorpo (anti-HLA-A, B, C, DR ou DQ) observando a probabilidade de uma prova cruzada positiva com diferentes valores de MFI dos DSAs. As combinações entre eles também foram analisadas da mesma forma (N=175). Resultados: Na presença de um DSA exclusivo contra os grupos alélicos A, B e DR, com índice MFI acima de 5.000, todos os FCXM foram positivos. Com anticorpos exclusivamente contra os grupos C ou DQ, todos os casos com DSAs acima de 15.000 MFIs foram positivos. Com dois ou mais DSAs anti A e/ou B, e/ou DR, quando suas somas de MFIs excederam 5.000, todos os resultados de FCXM contra células B foram positivos. A presença de DSA anti-Classe I (A, B e A+B), independentemente do valor de MFI, foi responsável por 71% (N=424 de 601) da positividade de células T e 77% (N=460 de 661) nas células B. A presença apenas de DSAs anti Classe II (DR e DQ) foi responsável por 55% (N=168 de 303) da positividade FCXM em células B. A média geral do MFI dos DSAs foi maior no grupo FCXM positivo quando comparado ao crossmatch negativo. O grupo com somatória de DSAs A (N=217) mostrou que quando a soma era de 4.000 MFIs ou mais havia uma probabilidade 24 vezes maior de uma prova cruzada positiva de células B quando comparado com MFIs menores. Conclusões: Nossos resultados mostram uma forte associação entre o DSA MFI e o resultado do FCXM. Os dados aqui apresentados confirmam os resultados dos nossos estudos anteriores, justificando o padrão VXM utilizado pelo nosso centro, revelando-se uma boa ferramenta para agilizar a seleção de receptores de transplantes e facilitar a distribuição de órgãos de dadores nacionais.

27 November 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
EHElizabeth Hendren
Elizabeth Hendren
JLJames H. Lan
James H. Lan
MKMatthew Kadatz
Matthew Kadatz
DSDeirdre Sawinski
Deirdre Sawinski
RLRobert Liwski
Robert Liwski
JGJohn S. Gill
John S. Gill
Females have higher rates of rejection and allograft failure not due to death compared to males. Offspring living kidney donor transplants provide an opportunity to assess the role of maternal immune memory in outcome differences between sexes. Among adult living kidney donor recipients in the Scientific Registry of Transplant Recipients from 2000 to 2018, the cumulative incidence of graft loss was higher in female compared to male recipients p <0.001. Among females, the adjusted hazard ratio (AHR) for graft loss was similar in offspring and non-offspring donor transplant recipients (AHR = 1.07, 95% confidence interval (CI), 0.94 -1.22, p =0.3) while male recipients of offspring donor kidneys had a lower risk of graft loss compared to non-offspring donor recipients (AHR = 0.87, 95% CI 0.77, 0.99, p = 0.03). Among females, offspring donor recipients had a higher adjusted odds ratio (AOR) for rejection, (AOR, 1.33, 95% CI 1.06, 1.67, p = 0.02) but among males, the odds of rejection were similar in offspring and non-offspring donor recipients (AOR, 1.15, 95% CI 0.95, 1.39, p = 0.14). The findings indicate a role for maternal immune memory in sex differences in kidney transplant outcomes that should be verified with further immunological studies.